Article

Parasite Remedy Doesn't Change Course of Chagas Damage

Author(s):

Drug kills parasites but too late to prevent heart myopathy in Chagas Disease.

Chagas disease patients who got trypanocidal therapy with benznidazole had relief from the acute phase of the heart illness, but their cardiomyopathy continued to progress, a multi-national study in South America and Latin America found.

According to the US Centers for Disease Control and Prevention, the disease is caused by the parasite Trypanosoma cruzi, which is carried by insects and transmitted to people and animals by bug bites and is common in rural areas of Latin America. Globally it is the third most common parasitic disease.

Carlos Morilla, MD, and colleagues at Population Health Research Institute—Hamilton Health Sciences and McMaster University in Ontario, Canada studied 2,854 patients with heart failure due to Chagas.

They were randomized to benznidazole or placebo and followed for five years.

The drug did kill the parasite in about 2/3 of the patients, but there were no significant clinical cardiac benefits seen.

The study, first published in the New England Journal of Medicine, was highlighted Oct. 27 in JAMA.

Researcher hypothesized that different genetic subtypes of the parasite might be in different patients, possibly explaining why a third of the patients did not see a reduction of circulating parasites in their serum. .

Related Videos
The APAC Recap: Peripheral Artery Disease at CAPP Live 2024 with Bob Ross, PA-C | Image Credit: APAC
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.